Shares of AEterna Zentaris Inc. (AEZS) are down over 59% in pre-market trading today, following disappointing results from its phase III study of drug candidate Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer.
from RTT - Biotech http://ift.tt/2qoDiE9
via IFTTT
No comments:
Post a Comment